FDA Drug Labels: What Investors Skip (and Pay For)

Here is the Amtagvi label page on Drugs@FDA. In two minutes of reading, it reveals what the Iovance press release did not. Most biotech investors trade on headlines. They never read the definitive document the FDA publishes about an approved drug: the prescribing information, commonly called the drug label. It is free, public, legally binding, and tells you what the FDA actually approved, which is often narrower than what the company implied.

The Problem

Biotech investors evaluate drugs based on press releases, analyst reports, and management guidance. None of those are legally binding. The FDA drug label is. If the label restricts a drug to third-line use, the addressable market is third-line patients, not all patients with the disease. If the label requires a companion diagnostic, only patients who test positive for the biomarker are eligible. If the label carries a black box warning, commercial uptake will be slower than the revenue models assume. Skipping the label is skipping the fine print, and in biotech, the fine print is the TAM.

The Solution

You can find any FDA-approved drug’s label in two minutes and read the five sections that matter for stock analysis. No scientific background required.

Step 1: Find the Label

Go to Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Search the drug’s brand name or generic name. Click the approval date. Download the PDF labeled “Prescribing Information” or “Label.” For biologics, use the FDA’s Purple Book at purplebooksearch.fda.gov. For daily-updated labels, DailyMed (dailymed.nlm.nih.gov) mirrors the same content.

Some companies host labels on their investor relations pages, but those can lag behind the FDA version. Start at the source.

Step 2: Read Section 1: Indications and Usage

This is the approved indication: exactly what the FDA says the drug can treat. Every word matters.

Compare the company’s press release language (“our drug treats breast cancer”) to the label language (“in combination with fulvestrant for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy”). The label’s specificity defines the addressable market. If the label says third-line, the TAM is third-line patients. Not first-line. Not second-line.

Red flag: The label indication is narrower than what the company described in investor presentations. This means the FDA restricted the claim based on the data submitted, and the market opportunity is smaller than the company guided.

Step 3: Read Section 2: Dosage and Administration

How is the drug given? IV infusion every two weeks? Daily pill? Requires pre-medication?

This section determines commercial convenience. An oral drug that patients take at home competes differently than an IV drug that requires infusion center visits every two weeks. Pre-medications (steroids, antihistamines) add friction for patients and clinics.

Red flag: Dosing adjustments for renal impairment, hepatic impairment, or drug-drug interactions. Each required adjustment shrinks the addressable population and complicates prescribing.

Step 4: Read Section 6: Adverse Reactions

The safety tables in Section 6 show you what percentage of patients experienced each side effect, broken out by severity grade. Compare these rates against competitors’ labels.

Look for:

• Discontinuation rate: What percentage of patients quit the drug because of side effects?
• Serious adverse events (SAEs): Hospitalizations, life-threatening events, deaths
• Black box warning: The FDA’s most severe safety warning, appearing as a boxed statement at the top of the label. This is a commercial headwind; it gets cited in every physician conversation about the drug.

Red flag: A black box warning that the competitor’s label does not carry. This is a permanent competitive disadvantage.

Step 5: Read Section 8: Use in Specific Populations

Pregnancy, pediatrics, geriatrics, renal impairment, hepatic impairment. Each restriction here removes a slice of the patient population from the addressable market.

Red flag: Contraindicated in pregnancy (the strictest category) when the disease disproportionately affects women of childbearing age. Or “safety and effectiveness in pediatric patients have not been established” when pediatric patients are a meaningful share of the disease population.

Step 6: Read Section 14: Clinical Studies

This is the actual trial data the FDA reviewed. Tables of efficacy results, unfiltered by company PR. If the press release said “overall response rate of 40%,” check Section 14 to see whether that was 40% in a single-arm trial of 50 patients or 40% in a randomized Phase 3 of 500 patients. The denominator matters.

Red flag: Any discrepancy between the company’s public efficacy claims and the FDA label’s clinical study tables. The FDA’s numbers are definitive.

The Post-Approval Playbook

Labels change. When a drug gets a supplemental approval (an sBLA for biologics or sNDA for small molecules), the label expands to include the new indication. For large-cap pharma, label expansions often matter more than first approvals; a drug that adds a first-line indication can double or triple its addressable market.

Track label changes on Drugs@FDA by checking for newer approval dates under the same drug. Or use the FDA’s Orange Book (for small molecules) and Purple Book (for biologics) to see the current approved indications.

Red flag: A label under accelerated approval — this means the confirmatory trial is still pending, and the FDA can withdraw approval if it fails. The FDORA legislation of 2022 gave the FDA expedited withdrawal authority. Roughly 15% of accelerated approval oncology drugs are eventually withdrawn. Check whether the confirmatory trial has read out.

Common Mistakes Investors Make

Assuming the press release indication equals the label indication. It does not. Companies use the broadest language their lawyers allow. The FDA uses the narrowest language the data supports. Read Section 1.

Ignoring black box warnings in revenue models. A black box does not kill a drug, but it permanently limits peak sales. Build a 20-30% haircut into peak sales estimates for any drug with a boxed warning versus a competitor without one.

Not checking for accelerated approval status. An approved drug is not a permanently approved drug if the confirmatory trial is still running. Know the difference.

Using the company’s hosted label PDF instead of the FDA’s. Company websites can host outdated versions. Drugs@FDA and DailyMed are the authoritative sources.

Final Checklist

• Found the label on Drugs@FDA or DailyMed (not the company’s IR page)
• Read Section 1: exact indication, biomarker requirement, line of therapy
• Read Section 2: dosing route, frequency, pre-medications required
• Read Section 6: discontinuation rate, SAEs, black box warning
• Read Section 8: pregnancy, pediatric, geriatric restrictions
• Read Section 14: actual trial data tables, compared to company’s public claims
• Checked for accelerated approval status (confirmatory trial still pending?)
• Searched for supplemental approvals (label expansions post-launch)

The label is not the only document that matters. Read the trial data, too: /news/how-to-read-clinical-trial-press-release. But it is the one investors skip most often, and it is the one that costs them the most when they get the TAM wrong.

Iovance’s Amtagvi (lifileucel) press releases said “approved for advanced melanoma.” The label says it is for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation-positive, a BRAF inhibitor. That is a much smaller population than “advanced melanoma.” The label is the fine print. Read it before you size the market. For a recent commercial update, see the Amtagvi revenue analysis.

Find any FDA-approved drug’s label at Drugs@FDA. For daily-updated prescribing information, use the NIH’s DailyMed.